NASDAQ$ORGO
Organogenesis Holdings Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported financial results with revenue growth driven by advanced wound care products and strategic execution amidst pandemic challenges.
Organogenesis Holdings Inc. reported a 6% increase in net revenue for Q2 2020, reaching $69.0 million, driven by strong performance in Advanced Wound Care products. The company also reduced its net loss to $5.2 million and achieved positive Adjusted EBITDA of $274 thousand.
- Net revenue increased by 6% to $69.0 million compared to Q2 2019.
- Advanced Wound Care product revenue grew by 8% to $59.7 million.
- Net loss decreased by 46% to $5.2 million.
- Adjusted EBITDA improved to $274 thousand from a loss of $4.8 million in Q2 2019.
Headline financials
Revenue & EPS history
Organogenesis · Revenue · Quarterly
$69M
Revenue by segment
Organogenesis · $59.7M total across 1 segment · Q2 2020
- Advanced Wound Care$59.7M+8.1%100.0%
Forward guidance
The company is reinstating its fiscal year 2020 revenue guidance, originally issued on March 9, 2020 and now expects net revenue of between $273 million and $277 million, representing growth of approximately 5% to 6% year-over-year.
Tailwinds
- Reinstating formal financial guidance.
- Expected total revenue growth of 5% to 6% in 2020.
- Advanced Wound Care products revenue growth of approximately 7% to 8% year-over-year.
- Strong operating and financial performance expected over the balance of 2020.
- Guidance consistent with projections made in early March before the COVID-19 pandemic.
Headwinds
- Surgical & Sports Medicine products revenue decrease of approximately 3% to 8% year-over-year.
- Net revenue from the sale of PuraPly products decrease of approximately 13% to 15% year-over-year.
- Potential impact of COVID-19 pandemic on the company’s fiscal condition and results of operations.
- Risk of changes to reimbursement levels for the company’s products.
- Uncertainties related to economic, business, and competitive factors.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+2.8%
Avg return
Earnings day
+3.2%
Avg return
5 days after
+0.5%
Avg return
30 days after
47%
17 / 36 earnings
Positive
+102.3%
Q4 2024
Best reaction
-42.4%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | -6.2% | -5.9% | |
| Q4 2025 | -13.8% | -22.4% | -38.1% | |
| Q3 2025 | +44.1% | +66.6% | +21.9% | |
| Q1 2025 | -42.4% | -43.6% | -43.3% | |
| Q4 2024 | +102.3% | +95.8% | +46.6% | |
| Q3 2024 | +26.6% | +10.3% | +0.9% | |
| Q2 2024 | +2.0% | +6.4% | -1.2% | |
| Q1 2024 | +31.2% | +23.2% | +19.0% | |
| Q4 2023 | -16.3% | -20.3% | -18.6% | |
| Q3 2023 | +6.8% | +22.9% | +62.4% | |
| Q2 2023 | -25.7% | -27.0% | -31.6% | |
| Q1 2023 | +29.7% | +43.2% | +81.1% | |
| Q4 2022 | +11.0% | -2.9% | -13.1% | |
| Q3 2022 | -18.3% | -11.5% | -17.7% | |
| Q2 2022 | -25.2% | -26.6% | -44.0% | |
| Q1 2022 | +4.6% | +9.8% | -9.3% | |
| Q4 2021 | +18.1% | +15.6% | +2.4% | |
| Q3 2021 | -6.4% | -5.0% | -16.1% | |
| Q2 2021 | +1.9% | +2.5% | +8.2% | |
| Q1 2021 | -15.3% | -11.3% | -28.7% | |
| Q4 2020 | +3.8% | +8.5% | +31.4% | |
| Q3 2020 | +8.2% | +5.2% | +20.2% | |
| Q2 2020 | +0.7% | +1.5% | +3.2% | |
| Q1 2020 | -9.9% | -18.8% | +4.2% | |
| Q4 2019 | -16.2% | +11.6% | +23.5% | |
| Q3 2019 | +10.3% | +8.8% | -36.1% | |
| Q2 2019 | -4.7% | -10.8% | +26.5% | |
| Q1 2019 | -0.4% | +1.0% | +0.7% | |
| Q4 2018 | -3.0% | -5.3% | -16.8% | |
| Q4 2017 | -3.0% | -5.3% | -16.8% | |
| Q2 2018 | +0.3% | +0.2% | +0.1% | |
| Q1 2018 | +0.0% | +0.4% | +0.3% | |
| Q3 2017 | +0.1% | +0.1% | -1.0% | |
| Q2 2017 | +0.0% | +0.1% | +1.5% | |
| Q1 2017 | -0.3% | -0.3% | +0.5% | |
| Q4 2016 | +0.0% | +0.0% | +0.0% | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro